These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30068796)

  • 21. PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses.
    Tian H; Kang Y; Song X; Xu Y; Chen H; Gong X; Zhang W; Xu Y; Xia X; Gao X; Yao W
    Cancer Lett; 2020 Apr; 476():170-182. PubMed ID: 32092355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
    Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
    Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
    Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
    Front Immunol; 2018; 9():1613. PubMed ID: 30123214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia.
    Yang K; Xu J; Liu Q; Li J; Xi Y
    Pathol Res Pract; 2019 Feb; 215(2):265-271. PubMed ID: 30466764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical significance of PD‑L1 in colorectal cancer (Review).
    Ntomi V; Foukas P; Papaconstantinou D; Antonopoulou I; Pikoulis A; Panagiotides I; Pikoulis E; Syrigos K
    Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
    Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of exosomal PDL1 in tumour immune evasion.
    Daassi D; Mahoney KM; Freeman GJ
    Nat Rev Immunol; 2020 Apr; 20(4):209-215. PubMed ID: 31965064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
    Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
    Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of PD1/PD-L1 X-Aptamers.
    Wang H; Lam CH; Li X; West DL; Yang X
    Biochimie; 2018 Feb; 145():125-130. PubMed ID: 28912094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed death ligand 1 signals in cancer cells.
    Kornepati AVR; Vadlamudi RK; Curiel TJ
    Nat Rev Cancer; 2022 Mar; 22(3):174-189. PubMed ID: 35031777
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials.
    Reuss JE; Stern D; Foster JC; Ramaswami R; Lurain K; Chen HX; Streicher H; Kem R; Little RF; Sharon E
    JAMA Netw Open; 2020 Dec; 3(12):e2027110. PubMed ID: 33258905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
    Zuazo M; Gato-Cañas M; Llorente N; Ibañez-Vea M; Arasanz H; Kochan G; Escors D
    Ann Transl Med; 2017 Oct; 5(19):385. PubMed ID: 29114543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?
    Dasanu CA; Del Rosario M; Codreanu I; Hyams DM; Plaxe SC
    J Oncol Pharm Pract; 2019 Jan; 25(1):214-216. PubMed ID: 29933728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Checkpoints as a Target for Colorectal Cancer Treatment.
    Passardi A; Canale M; Valgiusti M; Ulivi P
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
    Menter T; Bodmer-Haecki A; Dirnhofer S; Tzankov A
    Hum Pathol; 2016 Aug; 54():17-24. PubMed ID: 27045512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer.
    Tamura T; Ohira M; Tanaka H; Muguruma K; Toyokawa T; Kubo N; Sakurai K; Amano R; Kimura K; Shibutani M; Maeda K; Hirakawa K
    Anticancer Res; 2015 Oct; 35(10):5369-76. PubMed ID: 26408698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives.
    Kourie HR; Awada G; Awada A
    Immunotherapy; 2017 Jun; 9(8):647-657. PubMed ID: 28653570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.
    Amarnath S; Mangus CW; Wang JC; Wei F; He A; Kapoor V; Foley JE; Massey PR; Felizardo TC; Riley JL; Levine BL; June CH; Medin JA; Fowler DH
    Sci Transl Med; 2011 Nov; 3(111):111ra120. PubMed ID: 22133721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression.
    Haile ST; Dalal SP; Clements V; Tamada K; Ostrand-Rosenberg S
    J Immunol; 2013 Sep; 191(5):2829-36. PubMed ID: 23918985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.